PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation - A possible target for ATRA response in AML without t(15;17)

Clinical Cancer Research

Volumn 19, Issue 9, 2013, Pages 2562-2571

  Bullinger, Lars ^a   Schlenk, Richard F ^a   Goẗz, Marlies ^a   Botzenhardt, Ursula ^a   Hofmann, Susanne ^a   Russ, Annika C ^a   Babiak, Anna ^a   Zhang, Lu ^a   Schneider, Vanessa ^a   Doḧner, Konstanze ^a   Schmitt, Michael ^b   Doḧner, Hartmut ^a   Greiner, Jochen ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKEMIA ANTIGEN; NUCLEOPHOSMIN; PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA; RETINOIC ACID; RETINOIC ACID RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL DIFFERENTIATION; DNA MICROARRAY; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HOX GENE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 17; CLINICAL TRIALS, PHASE III AS TOPIC; GENE EXPRESSION REGULATION, LEUKEMIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; K562 CELLS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, RETINOIC ACID; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; TRETINOIN;

EID: 84877094410     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2524     Document Type: Article

References (29)

1. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977;1:549-50. (Pubitemid 8045927)
2. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhao L, et al.Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72.
3. Claus R, Plass C, Armstrong SA, Bullinger L. DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. Future Oncol 2010;6:1415-31.
4. Maciejewski JP, Mufti GJ. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 2008;112:965-74.
5. Wouters BJ, Lowenberg B, Delwel R. A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood 2009;113:291-8.
6. Dohner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-74.
7. Schlenk RF, Dohner K, Kneba M, Götze K, Hartmann F, Del Valle F, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009;94:54-60.
8. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005;122:835-47. (Pubitemid 41345202)
9. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93. (Pubitemid 33741893)
10. Greiner J, Bullinger L, Guinn BA, Dohner H, Schmitt M. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res 2008;14:7161-6.
11. Passeron T, Valencia JC, Namiki T, Vieira WD, Passeron H, Miyamura Y, et al. Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. J Clin Invest 2009;119:954-63.
12. Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002;133:118-23. (Pubitemid 34279642)
13. van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998;102:1376-9. (Pubitemid 28435230)
14. Santamaría CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood 2009;114:148-52.
15. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006;103:2794-9.
16. Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley T, et al. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 2009;114:3299-308.
17. Kohlmann A, Bullinger L, Thiede C, Schaich M, Schnittger S, Döhner K, et al. Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways. Leukemia 2010;24:1216-20.
18. Bullinger L, Dohner K, Kranz R, Stirner C, Fröhling S, Scholl C, et al. An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 2008;111:4490-5.
19. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50. (Pubitemid 41528093)
20. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
21. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008;112:4202-12.
22. Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 2004;108:704-11. (Pubitemid 38076402)
23. Rucker FG, Sander S, Dohner K, Dohner H, Pollack JR, Bullinger L. Molecular profiling reveals myeloid leukemia cell lines to be faithful model systems characterized by distinct genomic aberrations. Leukemia 2006;20:994-1001. (Pubitemid 43797290)
24. Muindi JR, Frankel SR, Huselton C, DeGrazia F, Garland WA, Young CW, et al. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992;52:2138-42.
25. Nair KS, Zingde SM. Adhesion of neutrophils to fibronectin: role of the cd66 antigens. Cell Immunol 2001;208:96-106.
26. Greiner J, Wiehe J, Wiesneth M, Zwaka TP, Prill T, Schwarz K, et al. Transient genetic labeling of human CD34-positive hematopoietic stem cells using nucleofection. Transfusion Med Hemother 2004;31:136-41. (Pubitemid 39179066)
27. Greiner J, Dohner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia-definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 2006;91:1653-61. (Pubitemid 46039635)
28. De Carvalho DD, Binato R, Pereira WO, Leroy JM, Colassanti MD, Proto-Siqueira R, et al. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene 2011;30:223-33.
29. de Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010;10:775-83.